Private equity firm Ampersand Capital Partners has invested in Academia-focused CRO, Julius Clinical Research.
The Zeist, Netherlands-based clinical research organization (CRO) announced receipt of the “majority recapitalization” last week, adding that the money would fund the expansion of its scientific and therapeutic expertise as well as build its geographic footprint in Europe and North America to accelerate growth of its services.
CEO, Martijn Wallert said "Julius Clinical Research is extremely pleased to have secured the support of Ampersand to help expand our expertise and geographic reach as a global research and scientific partner to pharmaceutical and biotechnology companies.”
He added: “We are now entering the next phase in our development, pursuing accelerated growth through our partnership with Ampersand. Their expertise and resources will enable us to enhance our clinical support services and make an even larger contribution to advancing medical science and drug development globally.”
Julius Clinical also hired Daniel Spasic, founder and former CEO of TFS HealthScience, as its executive chairman.
According to Spasic “The Company's scientific heritage from UMC Utrecht and established KOL and research networks in CNS, renal, cardiometabolic and infectious diseases make it a highly differentiated CRO able to provide its customers with strong scientific support and clinical trial execution to advance new therapeutics and treatments for the benefit of patients globally."
Juluis Clinical joins bioanalytical CRO Alliance Pharma, iuvo BioScience and P95 BV on Ampersand’s list of clinical services investments.
Ampersand Vice President Hidde Van Kerckhoven said, "Our investment in Julius Clinical aligns well with Ampersand's strategy of supporting high quality companies with established leadership positions in attractive segments of the pharmaceutical outsourcing market.”
She added: “We believe the Company's scientific expertise, differentiated services offering and dedicated management team are strong foundations for future growth. Ampersand looks forward to supporting the Julius Clinical team in this next phase of the Company's growth journey."
DepositPhotos/keport